Feasibility study of weekly paclitaxel patients with pre-treatment (2 regimens) advanced/recurrent gastric cancer (OGSG 0602)

Feasibility study of weekly paclitaxel patients with pre-treatment (2 regimens) advanced/recurrent gastric cancer (OGSG 0602) - OGSG 0602

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000723

Enrollment

Registered

2007-06-01

Start date

2006-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced / Recurrent gastric cancer.

Interventions

Premedication: Dexamethazon 20mg should be administered 30 minutes before Paclitaxel therapy Paclitaxel is administered on day 1, 8, and day 15 in one course of 28 days. It will be repeated until

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. histologically proven gastric carcinoma 2. patients who received TS-1 or CPT-11 as a prior chemotherapy and enough treatment free period (TS-1: 2weeks, CPT-11: 2weeks) 3. with measurable lesions 4. age: 20<= years old 5. PS(ECOG): 0 &#8211; 2 6. without any other severe diseases WBC 3,000<= Neutrocyte 1,500mm3<= Hemoglobin 9.0 g.dl <= Platelet 100,000/mm3 <= Total bilirubin 1.5 mg/dl => AST, ALT within five times of normal range in each institute Serum creatinin 1.5 mg/dl >= ECG normal range 7. expected survival period: longer than 3 months 8. written informed consents

Exclusion criteria

Exclusion criteria: 1. cavity fluid which should be taken out 2. with double cancer and/or multiple cancer 3. patients with disorders on peripheral nerves 4. with active infectious disease which needs treatment 5. under the condition of diarrhea 6. with some mental and/or neural disorder which disturbs registration 7. under continuous steroids therapy 8. with other severe diseases(intestinal paralysis, intestinal obstruction, uncontrolled DM, pulmonary fibrosis, cardiac failure, or liver dysfunction) 9. pregnant and/or nursing women 10.with allergic history against medicines 11.with severe allergic response against medicine including cremoful 12.under Docetaxel or Paclitaxel therapy 13.doctors' stop not to register to the study

Design outcomes

Primary

Measure	Time frame
feasibility of the treatment (ratio of completion)	—

Secondary

Measure	Time frame
Incidence of adverse events, Response Rate,Time to treatment failure,Progression free survival, Overall survival	—

Countries

Japan

Contacts

Public ContactFurukawa Hiroshi

Sakai City Hospital Director

072-221-1700

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026